BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 27538562)

  • 1. Giant pubertal prolactinoma: Complete resolution following short term carbegoline treatment.
    Oguz A; Tuzun D; Sahin M; Gul K
    Niger J Clin Pract; 2016; 19(5):685-7. PubMed ID: 27538562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.
    Cackett P; Eunson G; Bath L; Mulvihill A
    Future Oncol; 2012 Dec; 8(12):1621-6. PubMed ID: 23231524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resolution of third nerve palsy following treatment of prolactinoma with cabergoline.
    Harries AM; Gittoes NJ; Mitchell RD
    Acta Neurochir (Wien); 2010 Oct; 152(10):1741-3. PubMed ID: 20623359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pituitary apoplexy associated with cabergoline therapy.
    Chng E; Dalan R
    J Clin Neurosci; 2013 Dec; 20(12):1637-43. PubMed ID: 24113159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.
    Delgrange E; Donckier J
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2755-6. PubMed ID: 9253367
    [No Abstract]   [Full Text] [Related]  

  • 6. Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma.
    McCall D; Hunter SJ; Cooke RS; Herron B; Sheridan B; Atkinson AB
    Clin Endocrinol (Oxf); 2007 Jan; 66(1):149-50. PubMed ID: 17201816
    [No Abstract]   [Full Text] [Related]  

  • 7. Impressive shrinkage of a giant prolactinoma treated with cabergoline in a prepubescent girl. What now?
    Christoforidis A; Tsakalides C; Anastasiou A; Pavlaki A; Dimitriadou M
    Neuro Endocrinol Lett; 2013; 34(4):275-7. PubMed ID: 23803868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
    Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
    Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactinomas and pregnancy.
    Molitch ME
    Clin Endocrinol (Oxf); 2010 Aug; 73(2):147-8. PubMed ID: 20550542
    [No Abstract]   [Full Text] [Related]  

  • 10. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.
    Colao A; Lombardi G
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2756. PubMed ID: 9253368
    [No Abstract]   [Full Text] [Related]  

  • 12. Cabergoline treatment in a case of macroprolactinoma after delivery.
    Falsetti L
    Acta Eur Fertil; 1995; 26(3):105-7. PubMed ID: 9098469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary gland: can prolactinomas be cured medically?
    Molitch ME
    Nat Rev Endocrinol; 2010 Apr; 6(4):186-8. PubMed ID: 20336161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain and optic chiasmal herniations into sella after cabergoline therapy of giant prolactinoma.
    Dhanwal DK; Sharma AK
    Pituitary; 2011 Dec; 14(4):384-7. PubMed ID: 19381817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactinoma presenting as painful postganglionic Horner syndrome.
    Talkad AV; Kattah JC; Xu MY; Orth EH; Chang JY
    Neurology; 2004 Apr; 62(8):1440-1. PubMed ID: 15111696
    [No Abstract]   [Full Text] [Related]  

  • 16. Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
    Laboy-Ortiz IE; Velez-Maymí S; Hernán Martínez J; Trinidad R; Mangual M; Sanchez A; Gutierrez M; Mansilla P; Rivera C; Palermo C; de Lourdes Miranda M; Brau R
    Bol Asoc Med P R; 2016; 108(1):31-36. PubMed ID: 29193928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of cabergoline in the treatment of macroprolactinoma].
    Dupuy O; Le Marec E; Mayaudon H; Rilminger H; Bordier L; Bauduceau B
    Presse Med; 2003 Jan; 32(2):71-2. PubMed ID: 12653031
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
    Delgrange E; Maiter D; Donckier J
    Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas.
    Kurosaki M; Kambe A; Watanabe T; Fujii S; Ogawa T
    Neurol Res; 2015 Apr; 37(4):341-6. PubMed ID: 25376133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia.
    Miki N
    Intern Med; 2001 Sep; 40(9):845-6. PubMed ID: 11579939
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.